1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Oncocyte Corporation (OCX)
  7. Quote


Oncocyte Stock Price

-0.11 (-3.13%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 254,005
Bid Price 3.22
Ask Price 3.41
News -
Day High 3.53


52 Week Range


Day Low 3.345
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncocyte Corporation OCX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.11 -3.13% 3.41 00:00:09
Open Price Low Price High Price Close Price Prev Close
3.53 3.345 3.53 3.41 3.52
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,763 254,005 $ 3.40 $ 862,761 - 3.17 - 6.25
Last Trade Time Type Quantity Stock Price Currency
16:01:27 1 $ 3.41 USD


Draw Mode:

Oncocyte Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 315.89M 92.64M 61.12M $ 1.22M $ - -0.47 -9.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -25.87k 5.30%

more financials information »

Oncocyte News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OCX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.353.53883.173.36424,0400.061.79%
1 Month3.984.003.173.45388,062-0.57-14.32%
3 Months5.265.483.174.17640,415-1.85-35.17%
6 Months4.456.253.174.59539,089-1.04-23.37%
1 Year3.496.253.174.66604,571-0.08-2.29%
3 Years3.496.253.174.66604,571-0.08-2.29%
5 Years3.496.253.174.66604,571-0.08-2.29%

Oncocyte Description

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.